Business
The limited supply of this common reagent is set to drive drug prices higher, but there are ways for companies to lessen the impact.
FEATURED STORIES
The rare disease drugmaker is facing potential competitors for achondroplasia drug Voxzogo. Is a big M&A deal with two approved assets enough to maintain investor interest?
A rapturous response to data published last year for Pelage’s hair loss candidate overwhelmed the biotech. Now, the company is ready to show the world the science behind the breakthrough.
Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb and AstraZeneca are all ramping up the use of AI, but drug discovery is not the primary success story—yet.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
AstraZeneca and Daiichi Sankyo’s Enhertu received supplemental Biologics License Application acceptance and U.S. priority review for the treatment of HER2-positive metastatic gastric – or gastroesophageal junction cancer.
THOR-707 is a non-alpha IL-2 candidate that is currently being studied in Phase I trials in solid tumors.
Arcus will pair its investigational anti-TIGIT antibody domvanalimab (AB154) with AstraZeneca’s Imfinzi (durvalumab), a checkpoint inhibitor, in a Phase III study with patients who have unresectable Stage III NSCLC.
On October 14th, Amolyt Pharma announced the first dosing in its Phase I trial of AZP-3601 in healthy subjects, a momentous occasion capping off years of hard work in pre-clinical development. The drug aims to walk the biological tightrope in the management of hypoparathyroidism, a rare disease causing muscular pain and cognitive challenges.
Recent Greenphire data shows new participant enrollment up 85% since slump in April.
Kidney disease hasn’t been an area of vibrant transformation, but it is emerging as a promising and area for diagnostic and therapeutic investigation following an explosion of foundational technologies in recent years, according to speakers at BIO-Europe® Digital, held virtually October 26-29.
Through this collaboration, Insitro will utilize its proprietary platform, Insitro Human (ISH), to create induced pluripotent stem cell (iPSC) derived disease models for both diseases.
Texas wants to get the word out: It’s not just for oil and pipelines anymore. The Lone Star State is a rapidly emerging biopharma hub, with more than just a lone focus on oncology.
Novartis is harnessing the power of Molecular Partners AG’s DARPin platform to develop two therapeutic candidates that could both be used to prevent and treat COVID-19 infection.
Find out which biopharma companies are raking in the cash this week, as companies from around the globe provide updates on their financing rounds and IPOs.